Avenue Therapeutics, which is a Fortress Biotech spinoff developing an IV formulation of the opioid tramadol, raised $33 million by offering 5.5 million shares at $6, the midpoint of the $5 to $7 lowered range. Avenue Therapeutics plans to list on the Nasdaq under the symbol ATXI. Oppenheimer & Co. acted as a lead manager on the deal.
The article Micro-cap opioid biotech Avenue Therapeutics prices IPO at $6, midpoint of the lowered range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.